Varied differentiation responses of human leukemias to bryostatin 1

Andrew Kraft, F. William, G. R. Pettit, M. B. Lilly

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Bryostatin 1, a macrocyclic lactone isolated from a marine bryozoan, has significant antineoplastic activity against the murine cell line P388. Like phorbol esters, bryostatin 1 is capable of binding to and activating protein kinase C, but these two compounds differ in the ability of bryostatin 1 to act as a tumor promoter. We have investigated whether bryostatin 1 can modulate the differentiated phenotype of fresh samples of human myeloid leukemia. We find that six of seven samples responded to bryostatin treatment with changes associated with a more differentiated phenotype including increases in macrophage-like morphology and an increase in adherence and OKM1 and α-naphthyl acetate esterase activity positivity. The percentage of cells within each sample evidencing these changes varied markedly among the seven patients' cells examined. Because of the effects of bryostatin on fresh samples we examined the ability of bryostatin to differentiate four HL-60 cell sublines obtained from different laboratories. We found that two of the cell lines did not respond either with an inhibition of growth or morphological change, while one was inhibited, and one showed both growth inhibition and some induction of macrophage-like morphology when treated with bryostatin. To test whether other differentiating agents would enhance the effects of bryostatin 1, we added tumor necrosis factor α and bryostatin to these four cell lines. The addition of both agents effected an additive inhibition of growth. These data suggest that bryostatin 1 alone or in combination with other biological response modifiers may have a role in the treatment of human leukemia.

Original languageEnglish (US)
Pages (from-to)1287-1293
Number of pages7
JournalCancer Research
Volume49
Issue number5
StatePublished - 1989
Externally publishedYes

Fingerprint

Bryostatins
Leukemia
Cell Line
Growth
Macrophages
Acetylesterase
Phenotype
Myeloid Leukemia
HL-60 Cells
Immunologic Factors
Phorbol Esters
Lactones
Carcinogens
Antineoplastic Agents
Protein Kinase C
bryostatin 1
Tumor Necrosis Factor-alpha
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kraft, A., William, F., Pettit, G. R., & Lilly, M. B. (1989). Varied differentiation responses of human leukemias to bryostatin 1. Cancer Research, 49(5), 1287-1293.

Varied differentiation responses of human leukemias to bryostatin 1. / Kraft, Andrew; William, F.; Pettit, G. R.; Lilly, M. B.

In: Cancer Research, Vol. 49, No. 5, 1989, p. 1287-1293.

Research output: Contribution to journalArticle

Kraft, A, William, F, Pettit, GR & Lilly, MB 1989, 'Varied differentiation responses of human leukemias to bryostatin 1', Cancer Research, vol. 49, no. 5, pp. 1287-1293.
Kraft, Andrew ; William, F. ; Pettit, G. R. ; Lilly, M. B. / Varied differentiation responses of human leukemias to bryostatin 1. In: Cancer Research. 1989 ; Vol. 49, No. 5. pp. 1287-1293.
@article{f07fd5d7658042eeb4ea5a1a777d1e53,
title = "Varied differentiation responses of human leukemias to bryostatin 1",
abstract = "Bryostatin 1, a macrocyclic lactone isolated from a marine bryozoan, has significant antineoplastic activity against the murine cell line P388. Like phorbol esters, bryostatin 1 is capable of binding to and activating protein kinase C, but these two compounds differ in the ability of bryostatin 1 to act as a tumor promoter. We have investigated whether bryostatin 1 can modulate the differentiated phenotype of fresh samples of human myeloid leukemia. We find that six of seven samples responded to bryostatin treatment with changes associated with a more differentiated phenotype including increases in macrophage-like morphology and an increase in adherence and OKM1 and α-naphthyl acetate esterase activity positivity. The percentage of cells within each sample evidencing these changes varied markedly among the seven patients' cells examined. Because of the effects of bryostatin on fresh samples we examined the ability of bryostatin to differentiate four HL-60 cell sublines obtained from different laboratories. We found that two of the cell lines did not respond either with an inhibition of growth or morphological change, while one was inhibited, and one showed both growth inhibition and some induction of macrophage-like morphology when treated with bryostatin. To test whether other differentiating agents would enhance the effects of bryostatin 1, we added tumor necrosis factor α and bryostatin to these four cell lines. The addition of both agents effected an additive inhibition of growth. These data suggest that bryostatin 1 alone or in combination with other biological response modifiers may have a role in the treatment of human leukemia.",
author = "Andrew Kraft and F. William and Pettit, {G. R.} and Lilly, {M. B.}",
year = "1989",
language = "English (US)",
volume = "49",
pages = "1287--1293",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Varied differentiation responses of human leukemias to bryostatin 1

AU - Kraft, Andrew

AU - William, F.

AU - Pettit, G. R.

AU - Lilly, M. B.

PY - 1989

Y1 - 1989

N2 - Bryostatin 1, a macrocyclic lactone isolated from a marine bryozoan, has significant antineoplastic activity against the murine cell line P388. Like phorbol esters, bryostatin 1 is capable of binding to and activating protein kinase C, but these two compounds differ in the ability of bryostatin 1 to act as a tumor promoter. We have investigated whether bryostatin 1 can modulate the differentiated phenotype of fresh samples of human myeloid leukemia. We find that six of seven samples responded to bryostatin treatment with changes associated with a more differentiated phenotype including increases in macrophage-like morphology and an increase in adherence and OKM1 and α-naphthyl acetate esterase activity positivity. The percentage of cells within each sample evidencing these changes varied markedly among the seven patients' cells examined. Because of the effects of bryostatin on fresh samples we examined the ability of bryostatin to differentiate four HL-60 cell sublines obtained from different laboratories. We found that two of the cell lines did not respond either with an inhibition of growth or morphological change, while one was inhibited, and one showed both growth inhibition and some induction of macrophage-like morphology when treated with bryostatin. To test whether other differentiating agents would enhance the effects of bryostatin 1, we added tumor necrosis factor α and bryostatin to these four cell lines. The addition of both agents effected an additive inhibition of growth. These data suggest that bryostatin 1 alone or in combination with other biological response modifiers may have a role in the treatment of human leukemia.

AB - Bryostatin 1, a macrocyclic lactone isolated from a marine bryozoan, has significant antineoplastic activity against the murine cell line P388. Like phorbol esters, bryostatin 1 is capable of binding to and activating protein kinase C, but these two compounds differ in the ability of bryostatin 1 to act as a tumor promoter. We have investigated whether bryostatin 1 can modulate the differentiated phenotype of fresh samples of human myeloid leukemia. We find that six of seven samples responded to bryostatin treatment with changes associated with a more differentiated phenotype including increases in macrophage-like morphology and an increase in adherence and OKM1 and α-naphthyl acetate esterase activity positivity. The percentage of cells within each sample evidencing these changes varied markedly among the seven patients' cells examined. Because of the effects of bryostatin on fresh samples we examined the ability of bryostatin to differentiate four HL-60 cell sublines obtained from different laboratories. We found that two of the cell lines did not respond either with an inhibition of growth or morphological change, while one was inhibited, and one showed both growth inhibition and some induction of macrophage-like morphology when treated with bryostatin. To test whether other differentiating agents would enhance the effects of bryostatin 1, we added tumor necrosis factor α and bryostatin to these four cell lines. The addition of both agents effected an additive inhibition of growth. These data suggest that bryostatin 1 alone or in combination with other biological response modifiers may have a role in the treatment of human leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0024504383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024504383&partnerID=8YFLogxK

M3 - Article

C2 - 2917358

AN - SCOPUS:0024504383

VL - 49

SP - 1287

EP - 1293

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 5

ER -